ICCC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IC

Mkt Cap

$97.0M

Volume

2.76K

Next Earnings

November 12th

Loading chart

IC

ICCCImmucell Corp

ICCC

Pay with—

Available Balance0.00

IC

Mkt Cap

$95.9M

Volume

2.76K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2ImmuCell Corporation (ICCC) reported Q2 2026 product sales of $7.19 million, up 11.5% year-over-year, with earnings of 20 cents per share versus 6 cents prior year. However, gross margins contracted significantly to 33.9% from 43.7% due to lower production volumes, material quality issues, and cost reclassifications. The stock declined 8.8% post-earnings. Management highlighted strong domestic sales growth of 27.7% and increased market share for First Defense, but noted international headwinds and manufacturing challenges. The company is investing $8 million in facility expansion expected to triple capacity by end of 2027.Zacks Investment Research · Aug 27, 2026

ImmuCell Q2 Profit Jumps as Margins RiseImmuCell reported Q2 2025 results with improved gross margins and completed First Defense production capacity expansion, but faces ongoing FDA approval delays for Retain product, creating uncertainty in near-term growth trajectory.The Motley Fool · Aug 15, 2025

PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday - BenzingaThe article discusses several stocks to watch heading into Wednesday, including PriceSmart, Kura Sushi, Manchester United, ImmuCell, and AZZ Inc. It provides details on the expected earnings and stock price movements for these companies.Benzinga · Jul 10, 2024

ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain®.GlobeNewswire Inc. · Jun 5, 2024

ImmuCell to Hold Virtual-Only Annual Meeting of StockholdersPORTLAND, Maine, June 04, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously disclosed in its Proxy Statement filed with the Securities and Exchange Commission (“SEC”) on April 26, 2024.GlobeNewswire Inc. · Jun 4, 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024Conference Call Scheduled for Wednesday, May 15, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, May 15, 2024 at 9:00 AM ETGlobeNewswire Inc. · May 8, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024.GlobeNewswire Inc. · Apr 9, 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ETGlobeNewswire Inc. · Feb 16, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023PORTLAND, Maine, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter of 2023, which ended December 31, 2023.GlobeNewswire Inc. · Jan 8, 2024

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023PORTLAND, Maine, Nov. 13, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023.GlobeNewswire Inc. · Nov 13, 2023

to start trading

IC

ICCCImmucell Corp

ICCC

Pay with—

Available Balance0.00

Your PositionYou don't own any ICCC yet.

Related Tickers

Earnings